Aurobindo Pharma’s generic of rheumatoid arthritis drug secures U.S. FDA nod

Generic drugmnaker Aurobindo Pharma has received U.S. Food and Drug Administration (U.S. FDA) last support to manufacture and marketplace Tofacitinib tablets, 5 mg and 10 mg.

The merchandise is bioequivalent and therapeutically equivalent to notation listed cause Xeljanz Tablets, 5 mg and 10 mg, of PF Prism C.V. It volition beryllium manufactured astatine subsidiary APL Healthcare’s Unit IV and launched immediately, Aurobindo Pharma said connected Thursday.

Tofacitinib tablets, 5 mg and 10 mg, person an estimated marketplace size of astir $494 cardinal successful the U.S., the institution said citing IQVIA MAT information for the 12 months ending April 2026. They are indicated for attraction of adults with moderately to severely progressive rheumatoid arthritis; progressive psoriatic arthritis; and moderately to severely progressive ulcerative colitis (UC).